Upregulation of the GABA transporter GAT-1 in the gracile nucleus in the spared nerve injury model of neuropathic pain

NEUROSCIENCE LETTERS

卷:480

Article

Gosselin, Romain-Daniel^1,2,3  Bebber, Damien^1,2,3  Decosterd, Isabelle^1,2,3 

[1] Univ Hosp Ctr, Pain Res Unit, Dept Anesthesiol, CH-1011 Lausanne, Switzerland

[2] Univ Lausanne, CH-1011 Lausanne, Switzerland

[3] Univ Lausanne, Dept Cell Biol & Morphol, CH-1005 Lausanne, Switzerland

关键词: Neuropathic pain;    Glia;    Astrocytes;    Gracile;    GABA;    Transporter;   

DOI  :  10.1016/j.neulet.2010.06.023

来源: Elsevier

【 摘 要 】

Neuropathic pain is a major health issue and is frequently accompanied by allodynia (painful sensations in response to normally non-painful stimulations), and unpleasant paresthesia/dysesthesia, pointing to alterations in sensory pathways normally dedicated to the processing of non-nociceptive information. Interestingly, mounting evidence indicate that central glial cells are key players in allodynia, partly due to changes in the astrocytic capacity to scavenge extracellular glutamate and gamma-aminobutyric acid (GABA), through changes in their respective transporters (EAAT and GAT). In the present study, we investigated the glial changes occurring in the dorsal column nuclei, the major target of normally innocuous sensory information, in the rat spared nerve injury (SNI) model of neuropathic pain. We report that together with a robust microglial and astrocytic reaction in the ipsilateral gracile nucleus, the GABA transporter GAT-1 is upregulated with no change in GAT-3 or glutamate transporters. Furthermore, [(3)H] GABA reuptake on crude synaptosome preparation shows that transporter activity is functionally increased ipsilaterally in SNI rats. This GAT-1 upregulation appears evenly distributed in the gracile nucleus and colocalizes with astrocytic activation. Neither glial activation nor GAT-1 modulation was detected in the cuneate nucleus. Together, the present results point to GABA transport in the gracile nucleus as a putative therapeutic target against abnormal sensory perceptions related to neuropathic pain. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

【 授权许可】

Free